Skip to main content
SpringerLink
Log in

Techniken, Indikationen, Ergebnisse

Stenting der peripheren Arterien

  • Fortbildung
  • Schwerpunkt Angiologie
  • Published:
CardioVasc Aims and scope

Bei Patienten mit symptomatischer arterieller Verschlusskrankheit wird die perkutane Behandlung als „first line“-Therapie durchgeführt. Nach Rekanalisierung und Dilatation der arteriellen Obstruktionen werden zur Stabilisierung Gefäßstützen implantiert, was zu einem chronischen Trauma der Gefäßwand führt, mit Restenose und Reverschluss als Folge. Aktuelle Entwicklungen der Ballon- und Stent-Technologie führen zu zunehmend besseren Ergebnissen.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3
Abb. 4

Literatur

  1. Krankenberg H, Schlüter M, Steinkamp HJ et al. Nitinol Stent Implantation Versus Percutaneous Transluminal angioplasty in Superficila Femoral Artery Lesions up to 10 cm in Length. The Femoral Artery Stenting Trial (FAST). Circulation. 2007;116–124

    Google Scholar 

  2. Scheinert D, Scheinert S, Sax J et al. Prevalence and clinical impact of stent fractures after femoropopliteal stenting. J Am Coll Cardiol. 2005;45:312–5

    Article  Google Scholar 

  3. Matsumura JS, Yamanouchi D, Goldstein JA et al. The United States StuDy for EvalUating EndovasculaR TreAtments of Lesions in the Superficial Femoral Artery and Proximal Popliteal By usIng the Protege EverfLex NitInol Stent System II (DURABULITY II). J Vasc Surg. 2013;58:73–83

    Article  Google Scholar 

  4. Vardi M, Novack V, Pencina et al. Safety and Efficacy Metrics for Primary Nitinol Stenting in Femoropopliteal Occlusive Disease: A Meta-analysis and critical Examination of Current Methodologies. Catheter Cardiovasc Interv. 2014;83:975–83

    Article  Google Scholar 

  5. Werner M, Paetzold A, Banning-Eichenseer U et al. Treatment of complex atherosclerotic femoropopliteal artery disease with a self-expanding interwoven nitinol stent: midterm results from the Leipzig SUPERA 500 registry. EuroIntervention. 2014;10(7):861–8

    Article  Google Scholar 

  6. Tepe G, Zeller T, Albrecht T et al. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N Engl J Med. 2008;358:689–99

    Article  CAS  Google Scholar 

  7. Medizinischer Dienst des Spitzenverbandes Bund der Krankenkassen. Drug Eluting Balloons (DEB) bei pAVK — Nutzenbewertung und Indikationskriterien. Version 2.0 vom 28.4.2017. https://www.mds-ev.de

  8. Schneider P. At VIVA 2017. Four-Year Results of the INPACT.SFA TRIAL. Drug-Coated Balloon Catheter vs an Uncoated Balloon Catheter in Femoropopliteal Lesions. DAIC 2017: September 14

  9. Duda SH, Bosiers M, Lammer J et al. Sirolimus-eluting versus bare nitinol stent for obstructive superficial femoral artery disease: the SIROCCO II trial. J Vasc Interv Radiol. 2005;16:331–8

    Article  Google Scholar 

  10. Dake MD, Ansel GM, Jaff MR et al. Zilver PTX Investigators. Paclitaxel-eluting stents show superiority to balloon angioplasty and bare metal stents in femoropopliteal disease: twelve-month Zilver PTX randomized study results. Circ Cardiovasc Interv. 2011;4:495–504

    Article  CAS  Google Scholar 

  11. Gray WA, Keirse K, Soga Y et al. A polymer-coated, paclitaxel-eluting stent (Eluvia) versus a polymer-free, paclitaxel-coated stent (Zilver PTX) for endovascular femoropopliteal intervention (IMPERIAL): a randomised, non-inferiority trial. Lancet. 2018; https://doi.org/10.1016/S0140-6736(18)32262-1

  12. Davaine JM, Querat J, Kaladji A et al. Treatment of TASC C and D Femoropoliteal Lesions with Paclitaxel eluting Stents: 12 month Results of the STELLA-PTX Registry. Eur J Vasc Endovasc Surg. 2015;50(5):631–7

    Article  CAS  Google Scholar 

  13. Goueffic Y et al. BATTLE: Randomised controlled trial at one year-paclitaxel-eluting stent vs. bare metal stent. Late-breaking trials and first-on-podium presentations: Vortrag beim Charing Cross International Symposium, 24. April 2018, London

  14. Liistro F. Preliminary data on DRASTICO RCT comparing DCB vs. DES in the treatment of FemPop disease in real world. Leipzig Interventional Course. 24. Januar 2017; https://linc2017.cncptdlx.com/media/1430_Francesco_Liistro_24_01_2017_Room_6_-_Speakers_corner.pdf

  15. Scheinert D. Real PTX RCT: 3 year data from a randomized comparison of DCB vs. DES in femoropopliteal lesions. Leipzig Interventional Course. 31. Januar 2018; https://linc2018.cncptdlx.com/media/1055_Dierk_Scheinert_31_01_2018_Room_5_-_Global_Expert_Exchange.pdf

  16. Hong SJ, Ko YG, Shin DH et al. Outcomes of Spot Stenting Versus Long Stenting After Intentional Subintimal Approach for Long Chronic Total Occlusions of the Femoropopliteal Artery. J Am Coll Cardiol Interv. 2015;8:472–80

    Article  Google Scholar 

  17. Ko YG. Comparison of Primary Long Stenting Versus Primary Short Stenting For Long Femoropopliteal Artery Disease (PARADE). Leipzig Interventional Course. 31. Januar 2018; https://linc2018.cncptdlx.com/media/1400_Young-Guk_Ko_31_01_2018_Room_7_-_Speakers_corner.pdf

  18. Sigl M, Dudeck O, Jung J et al. Multiple stent delivery system Multi-LOC, a new technology for spot-stenting of femoropopliteal artery-proof of concept in a preclinical large animal model. Vasa. 2017;46:446–51

    Article  Google Scholar 

  19. Amendt K, Beschorner U, Waliszewsky M et al. First clinical experience with the Multi-LOC multiple stent delivery system for fokal stenting in long femoro-popliteal lesions. Vasa. 2017;46:452–61

    Article  Google Scholar 

  20. Amendt K. All Comers Study with the VascuFlex Multi-LOC spot stenting device: 12-month results. Leipzig Interventional Course. 30. Januar 2018; https://linc2018.cncptdlx.com/media/1045_Klaus_Amendt_30_01_2018_Room_1_-_Main_Arena_1_v2.pdf

Download references

Author information

Authors and Affiliations

  1. Innere Medizin I, Angiologie, Kardiologie, Diabetesfolgeerkrankungen, Diakonissenkrankenhaus Mannheim, Gefäßzentrum Oberrhein, Speyerer Straße 91-93, 68163, Mannheim, Deutschland

    Klaus Amendt

  2. I. Medizinische Klinik, Kardiologie, Angiologie, Pneumiologie, Intensivmedizin, Universitätsmedizin Mannheim, Mannheim, Deutschland

    Martin Sigl

Authors
  1. Klaus Amendt
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Martin Sigl
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Klaus Amendt.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Amendt, K., Sigl, M. Stenting der peripheren Arterien. CV 18, 48–54 (2018). https://doi.org/10.1007/s15027-018-1482-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15027-018-1482-0

Search

Navigation